Can-Fite BioPharma, Ltd. (CANF): Narxning daromadga nisbati

Can-Fite (CANF) tovar belgisi

Can-Fite BioPharma (CANF) laboratoriya majmuasi uzluksiz ishlamoqda va klinik sinovlar jadvaliga qat'iy rioya qilinishini ta'minlamoqda. Emittentning kelajagi psoriaz va jigar saratoniga qarshi dori vositalari uchun FDA tasdig'iga bog'liq. Ushbu narx-savdo ko'rsatkichi grafigi baholash tebranishlarini vizuallashtiradi, bunda 0.80 qiymati joriy darajani tavsiflaydi. Rivojlanish strategiyasi kengayishni tezlashtirish uchun litsenziyalash kelishuvlari va patentlarni maqsadli sotib olishga asoslangan.

CANF Can-Fite BioPharma P/S multiplikatori (04.07.2022 - 13.11.2026)

Can-Fite BioPharma, Ltd. (CANF) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- joriy kotirovkalar va o'rtacha qiymat prognozi:
Birja narxi canfite.com|CANF - Maqsadli narxlar grafigi
- birja kapitallashuvi ma'lumotlari:
Bozor qiymati Can-Fite BioPharma, Ltd.|CANF - Kompaniyaning to‘liq qiymati
- emitentning balans qiymati statistikasi:
Bitta aksiya hisobiga sof aktivlar qiymati Can-Fite BioPharma|CANF - Balans kapitallashuvi|Bozor qiymatining xususiy kapitalga nisbati canfite.com|CANF - Kompaniyaning yakuniy aktivlari
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Qarzning kapitalga nisbati Can-Fite BioPharma|CANF - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Can-Fite|CANF - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Can-Fite BioPharma, Ltd.|CANF - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli kredit va qarzlari Can-Fite BioPharma|Shoshilinch likvidlik canfite.com
- foyda va multiplikatorlar bo'yicha ma'lumotlar:
CANF - Kompaniyaning sof foydasi|Kutilayotgan sof daromad Can-Fite BioPharma|CANF - P/E multiplikatori|Forvard P/E multiplikatori Can-Fite BioPharma Ltd|CANF - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Can-Fite BioPharma, Ltd.|CANF - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Can-Fite BioPharma|CANF - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi canfite.com|CANF - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Can-Fite BioPharma
- emitentning tushumi va sotuvlari tafsilotlari:
CANF - Kompaniya daromadi|Kompaniya daromadi prognozi canfite.com|CANF - Kapitalizatsiyaning daromadga nisbati|Prognoz narxning daromadga nisbati Can-Fite BioPharma, Ltd.
Kompaniyaning jamlanma tahliliyoti:canfite.com
Can-Fite seriyali mahsuloti

Can-Fite BioPharma onkologiya va jigar yallig'lanish jarayonlarini davolash uchun maqsadli molekulalarni ishlab chiqishga e'tibor qaratadi. 0.80 ga teng bo'lgan P/S ko'rsatkichi, bozor kapitalizatsiyasini operatsion daromad bilan solishtirish orqali tushumning bir birligining bozor qiymatini belgilaydi. Agar biznesning fundamental ko'rsatkichlari barqaror qolsa, ushbu koeffitsiyentning pasayishi ko'pincha aktivning qadrini past baholaganini anglatadi. Narx-sotuvlar nisbatining dinamikasini tahlil qilish orqali investor aksiya narxi va kompaniyaning haqiqiy o'sish sur'atlari o'rtasidagi farqni zudlik bilan aniqlashi mumkin.

Raqobatdosh kompaniyalar

INCY - Sotuvga nisbatan narx|Narxning daromadga nisbati HUTCHMED HCM|Nuvation Bio Inc - Narxning daromadga nisbati|DAWN - Narxning daromadga nisbati|Sotuvga nisbatan narx Monopar Corp|INBX: P/S multiplikatori|Narx/daromad multiplikatori I-Mab Biopharma IMAB|Kapitalizatsiyaning daromadga nisbati FENC|Sotuvga nisbatan narx Heron Therapeutics Inc HRTX|Kapitalizatsiyaning daromadga nisbati NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Bozor kapitallashuvining daromadga nisbati|Corbus Pharmaceuticals - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati BCAB (BioAtla, Inc.)|LIXT: P/S multiplikatori|Sotuvga nisbatan narx Citius Pharmaceuticals, Inc. (CTXR)|Narxning daromadga nisbati Cellectar Biosciences|BLRX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori APRE|P/S multiplikatori kaziatherapeutics.com (KZIA)|Narxning daromadga nisbati Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Narxning sotuvga nisbati|CMRX: Kapitalizatsiyaning daromadga nisbati|Sotuvga nisbatan narx cyclacel.com|GTHX: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Kronos Bio Inc|KTRA (Kintara) - P/S multiplikatori|P/S multiplikatori Oncternal Corp|Narxning daromadga nisbati Portage Biotech Inc. (PRTG)